We evaluated the incidence, the risk factors, and the outcome of late-onset noninfectious pulmonary complications (LONIPCs) among 50 patients who underwent allogeneic stem cell transplantation from unrelated donors. Of the 39 patients surviving at least 3 months, 10 (26%) fulfilled the diagnostic criteria of LONIPCs and were further subclassified as having bronchiolitis obliterans (four patients), bronchiolitis obliterans with organizing pneumonia (four patients), and interstitial pneumonia (two patients). Two patients had a durable partial remission after treatment with prednisone and cyclosporine; the remaining eight patients did not respond to treatment and five of them died of respiratory failure. Advanced stage of disease at transplant and chronic extensive graft-versus-host disease (GVHD) were significantly associated with the development of LONIPCs. Pulmonary function test (PFT) results before transplantation were similar in all patients, but patients with LONIPCs had a significant decrease in PFT indexes at the third month after BMT compared with controls. Moreover, the rate of cyclosporine taper during the fourth and fifth months after BMT was significantly more rapid in patients with LONIPCs than in controls, suggesting that the risk of LONIPCs may be influenced by a faster reduction of GVHD prophylaxis.
tions; stem cell transplantation; unrelated donor; chronic graft-versus-host disease; cyclosporine Transplantation with allogeneic marrow or peripheral blood haematopoietic precursors has been increasingly performed for a wide variety of haematological diseases in the last two decades. However, despite improvement in supportive care, the risk of morbidity and mortality related to this procedure continues to be a major concern for physicians and patients. Pulmonary complications occur in 40-60% of patients undergoing allogeneic transplantation, causing 10-40% of transplant-related deaths. 1 The spectrum of pulmonary complications includes infectious and noninfectious conditions. These are classified as early or late depending on whether they occur before or after 100 days post transplantation. The term late-onset noninfectious pulmonary complications (LONIPCs) has been used as a generic term for different entities occurring later than 3 months after transplant, such as idiopathic pneumonia, bronchiolitis obliterans, and lung fibrosis.
The pathogenesis of LONIPCs is unclear at present. Radiation, and cytotoxic or immunosuppressive drugs used in myeloablative treatment or in graft-versus-host disease (GVHD) prophylaxis may be involved. However, several studies in children and adults showed a strong association between LONIPCs and chronic GVHD. [2] [3] [4] [5] [6] [7] These studies focused on patients reinfused mostly with marrow progenitors from HLA-identical sibling donors. Since the incidence of chronic GVHD may be increased by the disparity of HLA matching and by the use of peripheral blood stem cells, 8, 9 which have largely replaced bone marrow because of their relative ease of collection and the quicker engraftment kinetics, it may be hypothesized that LONIPC associated with GVHD is enhanced in the unrelated setting. For this reason, we retrospectively evaluated the incidence and the outcome of LONIPCs in 50 patients who underwent allogeneic stem cell transplantation from unrelated donors in order to identify one or more risk factors.
Patients and methods

Patient population
In all, 50 consecutive patients with malignant haematological diseases who received allogeneic stem cell transplantation from unrelated donors at our Bone Marrow Unit between January 1997 and April 2002 were retrospectively analysed. The incidence, the risk factors, and the outcome of LONIPCs were evaluated in the 39 patients who survived at least 3 months after transplantation.
The clinical characteristics of the patients are shown in Table 1 . Median age at transplant was 32 years (range 14-56). Out of 39 patients, 27 (69%) were men. A total of 15 patients (39%) had a history of smoking and eight patients (21%) had been previously diagnosed with pulmonary disease (mainly asthma or recurrent bronchitis). Haematological diseases were acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), lymphoma, myelodysplastic syndrome (MDS), and idiopathic myelofibrosis (IM). A total of 15 patients (38%) were transplanted in an early phase of the disease (five patients with ALL in first remission, eight with CML in the chronic phase, and two with untreated MDS or IM), whereas the remaining 24 patients (62%) were in a late phase of the disease (20 patients with ALL in second or further remission, two with CML in the blastic phase, and two with lymphomas pretreated with at least two chemotherapy lines).
Transplant-related data
Conditioning regimen included total body irradiation (TBI) and 60 mg/kg cyclophosphamide (CY) over 2 days for 36 out of 39 patients (92%). Three patients received 16 mg/kg busulphan and CY at the same dose. TBI was performed at two different radiotherapy departments with an anteriorposterior set-up and was delivered by a linear accelerator at a total dose of 12 Gy in six fractions over 3 days, with a dose rate of 5-7 cGy/min. GVHD prophylaxis included 3 mg/kg/day cyclosporine A (CyA) i.v. in continuous infusion starting from day 1 and methotrexate (MTX) (15 mg/m 2 on day 1, 10 mg/m 2 on days 3, 6, and 11). In seven cases, total MTX dose was reduced for concomitant severe mucositis. CyA was given orally in two doses as soon as the patients were able to have an oral intake; CyA was continued up to day 100, then tapered according to the clinical and haematological assessment of the patient, with the aim of stopping definitively GVHD prophylaxis on day þ 180. Rate of Cya taper between days 100 and 180 could be modified because of Cya toxicity, relapse either molecular or haematological, mixed chimaerism, GVHD, or infections.
Cytomegalovirus (CMV) infection was monitored weekly by CMV antigenemia. If CMV antigenemia tests became positive, patients were treated with ganciclovir.
The assessment and grading of acute and chronic GVHD was primarily based on clinical findings and following the commonly accepted diagnostic criteria. 10, 11 In particular, chronic GVHD was diagnosed according to the grading scheme proposed in 1980 and based on the data of 20 subjects from Seattle. It was classified as limited (only localized skin and/or liver involvement) or extensive (generalized skin involvement or limited disease plus involvement of other organs). Extensive chronic GVHD was diagnosed on a clinical basis, supported by results from haematopoietic and chemical parameters, skin and liver biopsies, and Shirmer's test.
First-line therapy for acute GVHD of at least grade II was 5 mg/kg/day CyA and 2 mg/kg/day methylprednisone i.v. If no clinical response was obtained, anti-human Tlymphocyte rabbit serum ATG Fresenius was administered. Extensive chronic GVHD was treated with 3-5 mg/kg/day CyA and 1-5 mg/kg/day prednisone. The therapeutic choices were represented by tacrolimus, mycophenolate mofetil (MMF), or thalidomide.
LONIPCs diagnosis
Patients were clinically examined weekly during the first 3 months after transplantation, then every 2 weeks. Thorax X-ray and high-resolution computer tomography (CT) scan were performed in case of respiratory symptoms or fever. Pulmonary function tests (PFTs) were routinely performed a week before BMT and after 3, 6, 12, and 24 months, then repeated on the basis of clinical suspicion. PFTs were performed according to the American Thoracic Society Guidelines. 12 The following parameters were evaluated: forced expiratory volume in 1 s (FEV 1 ), expressed as a ratio of the forced vital capacity (FVC) or FEV 1 /FVC, vital capacity (VC), and diffusion capacity of carbon monoxide A diagnosis of LONIPCs was made in patients developing symptoms of lung disease including cough, wheezing, dyspnoea, and radiological abnormalities after 3 months from transplantation without any evidence of an infectious cause. To exclude infection, standard culture and staining methods for bacterial, viral, and protozoan pathogens were employed. Clinical and radiological findings had to be associated with abnormal PFT results or pertinent pathologic changes on lung biopsy. Once a patient was identified as having LONIPCs, a further classification was made on the basis of clinical, radiologic, PFT, and histologic findings. Patients were classified as having bronchiolitis obliterans (BO) if they showed FVC % predicted X80% and FEV 1 /FVC o70%. 13 A histologic diagnosis was required to classify patients as having bronchiolitis obliterans with organizing pneumonia (BOOP) or interstitial pneumonia (IP).
14 Histological specimens were obtained by transbronchial biopsy in one patient, CTguided lung biopsy in two, and after autopsy in the other three patients. In seven patients, a bronchoscopy with broncho-alveolar lavage was performed to exclude an infective aetiology.
Statistical analysis
Patients with and without LONIPCs were compared on the basis of several clinical characteristics of the patients and of the graft. Comparison of categorical variables was made by means of w 2 statistics or Fisher's exact test, and comparison of continuous values was made with the two sides Student's t-test. A P-value o0.05 was considered to be statistically significant.
Results
Clinical features at presentation (Table 2)
Of the 39 patients surviving at least 3 months after transplant, 10 patients (26%) fulfilled the diagnostic criteria of LONIPCs. LONIPCs were diagnosed at a median of 8 months after transplantation (range 3-11). Symptoms were cough and/or dyspnoea in all patients; one of them had fever as well. The first symptoms appeared between 1 and 4 months (median 2 months) before diagnosis and start of treatment. All the patients developed chronic GVHD before diagnosis of LONIPCs. GVHD was extensive with involvement of the skin, liver, mucosa, or gut in eight patients and limited with involvement of the skin or liver in the other two cases. The 10 patients with LONIPCs were further subclassified as having BO (four patients), BOOP (four patients), and IP (two patients).
The diagnosis of BO was mainly based on the obstructive pattern detected by PFTs, with a decrease in FEV 1 /FVC from a median of 83% (range 80-83%) before transplant to a median of 54% (range 50-56%) at the time of pulmonary complications. Abnormalities were found on chest radiography and CT scan in only one patient; this patient developed patchy opacities during the disease.
The four patients with BOOP had abnormal PTFs, with a mainly obstructive pattern in two patients and a mainly restrictive pattern in the other two; in all four patients, chest CT showed patchy infiltrates or opacities. All patients underwent bronchoscopy with bronchoalveolar washing negative for bacteria, fungi, and viruses, and three patients underwent transbronchial biopsy. One patient had histological confirmation of BOOP after transbronchial biopsy, one after CT-guided lung biopsy, and the other two after autopsy.
The two patients with IP had bilateral diffuse infiltrates on CT scan and no evidence of an infective cause after bronchoscopy. Histological specimens obtained in one patient after CT-guided lung biopsy and in the other after autopsy examination showed lymphocytic IP.
Outcome
All patients with LONIPCs were treated with 2-5 mg/kg/ day prednisone. CyA was added, or its dosage was increased if it was already part of the treatment, in nine patients; tacrolimus was initiated in three patients, thalidomide in one patient, and MMF in another one. Two patients had a stable partial response: one patient with BO showed a clinical improvement with discontinuation of oxygen support and PFT stability, and the other patient with BOOP had a reduction of infiltrates on CT. Both patients are still being treated with low-dose prednisone and CyA 12 and 7 months after the diagnosis of the pulmonary complication, respectively. The remaining eight patients died after a median of 3 months after the onset of LONIPCs (range 2-26 months). LONIPC was one of the main causes of death, directly or through a pulmonary infection, in five patients; the other three deaths were attributed to thrombotic thrombocytopenic purpura, probably due to tacrolimus, leukaemia relapse, and GuillainBarre`syndrome, respectively.
Risk factors
We compared PFT results of the patients with and without LONIPCs before and after transplant. Pre-BMT PFTs of the patients with LONIPCs were similar to controls; however FEV 1 /FVC, VC, and DLCO significantly decreased 3 months after BMT in patients who developed LONIPCs and worsened at the following evaluation (Table 3) .
Patients with LONIPCs and those without were compared on the basis of several clinical features and of graft parameters. Advanced-phase disease at the time of transplantation and chronic extensive GVHD were more frequent in patients with LONIPCs (P ¼ 0.01 and 0.006, respectively) ( Table 4) .
GVHD prophylaxis was based on MTX and CyA for all the patients. We compared the total amount of MTX per m 2 and the rate of CyA taper during the first 6 months after BMT between patients with LONIPCs and those without.
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We observed no significant difference for total MTX dose; however, patients with LONIPCs had a significantly more rapid reduction of Cya doses during the fourth and fifth months after BMT compared to controls (Table 5) .
Discussion
In our population, the incidence of LONIPCs was 26%, which is higher than that reported on previous papers (range 3-23.7%). [4] [5] [6] [13] [14] [15] This can be partially explained by the heterogeneity of the populations examined (including children or adults, matched-related or unrelated donors), the different source of stem cells reinfused, and the different conditioning regimens and GVHD prophylaxis. Moreover, the adherence to the diagnostic criteria of LONIPCs, which implies clinical, functional, and pathological evaluations, may create a bias and prevent comparison of results from different investigators. One of the reasons for the higher incidence of LONIPCs in our paper is that we investigated patients exclusively transplanted from unrelated donors. Two previous authors compared incidence between patients receiving related and unrelated donor transplants; Shultz and co-workers 5 found that it was enhanced up to 44.4% in the second group, but this difference was not confirmed by Sakaida et al. 15 Clinical symptoms of LONIPCs may be insidious at the beginning of the disease and routine radiological examination may be normal, too. High-resolution CT was superior to thorax X-ray in our experience, since it identified initial abnormalities in two patients with BOOP and one patient with IP, who had normal thorax X-ray.
PFTs are not generally considered specific. An impairment of DLCO has been noted in a significant proportion ASCT ¼ autologous stem cell transplantation; TBI ¼ total body irradiation; BM ¼ bone marrow; MTX ¼ methotrexate; CMV ¼ cytomegalovirus.
Pulmonary complications after stem cell transplantation F Patriarca et al (up to 80%) of survivors to BMT, even in those in good health, [16] [17] [18] [19] [20] whereas restrictive ventilatory defects or obstructive lung syndrome have been demonstrated in a minority of patients and have been associated with an increase in nonrelapse mortality. 21 In our series, although all the patients had similar PFT results before BMT, those who developed LONIPCs had a significant impairment of all PFT indexes at the third month, about 5 months before the median time of LONIPCs overt diagnosis. Thus, every effort should be made to make a correct and quick diagnosis, with radiological and pathological tools, on the patients who present an alteration of PFTs precociously. On the other hand, the short period between BMT and evidence of deterioration of PFT tests suggested a role of drugs or radiations used in the conditioning regimen or in GVHD prophylaxis, such as MTX, in initiating the damage of the lung tissue. [22] [23] [24] [25] Open lung biopsy is generally considered the golden standard tool for the diagnosis of LONIPCs and for the subclassification of the different pathological entities, 1 in particular BOOP and IP. However, it is an invasive procedure with a major risk of complications, and is reserved to a minority of patients (13-61% in the published papers). [4] [5] [6] In our paper, all the four diagnoses of BO were based on clinical and PFT pictures, whereas one patient with IP and one patient with BOOP underwent lung biopsies during the diagnostic process and further three patients at autopsy. Transbronchial biopsy, even less invasive, could not substitute open lung examination, since its findings were nondiagnostic in two out of three cases examined.
In our series, advanced stage of disease before transplantation and development of extensive chronic GVHD were significantly associated with LONIPCs. Most investigators agree that chronic GVHD is a powerful risk factor for LONIPCs, [2] [3] [4] [5] [6] [7] but there is disagreement about other factors such as type of conditioning regimen, acute GVHD, demographic characteristics of donors and recipients, and older age. These have been shown to correlate with LONIPCs in some studies 6 but not in others. 4 A possible explanation for the association between advanced stage of disease before transplantation and LONIPCs may be the high amount of drugs administered to the patients, which could accumulate and damage the lung tissue. Moreover, patients with advanced diseases could have had their GVHD prophylaxis tapered faster to control their disease; the reduction of immunosuppressant drugs could facilitate the development of chronic GVHD.
The role of GVHD prophylaxis in the development of LONIPCs has been investigated in patients who received different regimens of prophylaxis. Treatment with CyA and prednisone was associated with a higher incidence of LONIPCs, 4 whereas treatment with MTX and T-cell depletion did not. 5 Since all our patients received the same type of GVHD prophylaxis based on CyA and MTX, we could analyse the possible association of LONIPCs with the amount of drugs received. No correlation with MTX total dose was noted, but a significant difference in the rate of CyA dose reduction was observed between patients with and without LONIPCs, during the fourth and fifth months after BMT and before diagnosis of LONIPCs. We retrospectively evaluated reasons that could explain the increased rate of Cya taper in LONIPC patients and they were as follows: renal and neurological toxicity of cyclosporine (three patients), mixed chimaerism (three patients), molecular relapse (one patient), and late phase of disease at transplantation with high-risk of relapse (two patients). All these 10 patients who had their GVHD prophylaxis tapered faster developed a chronic GVHD, with extensive involvement in eight of them.
Chronic GVHD is a major cause of morbidity and mortality, accounting for about 25-33% of deaths in longterm survivors of transplants. Moreover, it is one of the most significant predictors of nonrelapse mortality and the main cause of delay in recovering an adequate quality of life after the transplant. 26 Mortality related to chronic GVHD is largely attributable to immunodeficiency, infectious complications, and organ failures. On the other hand, patients developing this complication have a lower incidence of relapse. 27, 28 However, a few studies have shown that extensive GVHD had a detrimental effect, which was not counterbalanced by the benefit of the antileukaemic reaction, resulting in a poorer outcome.
29,30
Saikada et al 15 observed that patients with LONIPCs had significantly lower relapse rates of primary malignant disease than did non-LONIPC patients, but overall survival of the former group was not longer, because most LONIPC patients died of progressive respiratory failure. This was also confirmed in our study. In fact, five out of 10 patients with GVHD and LONIPCs died of progressive respiratory failure or/and pulmonary infections and only one of them showed a leukaemia relapse. Other authors [4] [5] [6] reported a better outcome of LONIPC patients than ours, with an improvement of lung function in 50-90% of the patients after an immunosuppressive treatment and a mortality rate ranging from 15 to 39% for pulmonary causes. [4] [5] [6] The high prevalence of pretreated patients in a late phase of the disease and the exclusive source of stem cells from unrelated donors might explain the little response to therapy and the poorer outcome of our patients in comparison with other series, which included also nonmalignant diseases or received mostly cells from sibling donors.
Methods to decrease the incidence of these complications have been developed, such as T depletion of the graft or in vivo modulation of T-cells post transplant, by prolonging CyA administration. In fact, a few clinical trials demonstrated that chronic GVHD could be reduced after allo-PBT from sibling donors by slowly tapering CyA and prolonging its administration beyond 6 months.
31-33
Our report confirms and extends these results, suggesting that a slower reduction of CyA doses could limit the involvement of lung by GVHD after BMT from unrelated donor.
In conclusion, in the unrelated setting, the incidence of LONIPCs was higher and the clinical outcome of patients was worse than that already reported in the matchedrelated setting. Chronic extensive GVHD and advanced stage disease at transplantation were clinical features significantly associated with LONIPC development. A decrease in FEV 1 /FVC and VC at the third month could help to select patients at high risk for this complication. Finally, a fast tapering of CyA prophylaxis could favour LONIPC development. 
